Skip to main content

Table 3 The most frequent 4th level ATC sub-classes according to prescription goals

From: Drug prescription goals in primary care: a cross-sectional study

GoalATC sub-classn (%)
Mortality
(n = 429)
Platelet aggregation inhibitors excl. Heparin (B01AC)51 (11.9%)
HMG CoA reductase inhibitors (statin) (C10AA)48 (11.2%)
Beta blocking agents, selective (C07AB)32 (7.5%)
ACE inhibitors, plain (C09AA)30 (7.0%)
Angiotensin II antagonists, plain (C09CA)22 (5.1%)
Morbidity
(n = 1128)
HMG CoA reductase inhibitors (statin) (C10AA)106 (9.4%)
Vitamin D and analogues (A11CC)74 (6.6%)
ACE inhibitors, plain (C09AA)65 (5.8%)
Beta blocking agents, selective (C07AB)59 (5.2%)
Calcium channel blockers, dihydropyridine derivatives (C08CA)54 (4.8%)
Platelet aggregation inhibitors excl. Heparin (B01AC)54 (4.8%)
Cure
(n = 587)
Penicillins with extended spectrum (J01CA)59 (10.1%)
Glucocorticoids (H02AB)38 (6.5%)
NSAID propionic acid derivatives (M01AE)31 (5.3%)
Selective serotonin reuptake inhibitors (N06AB)29 (4.9%)
Imidazole and triazole derivatives for topical use (D01AC)25 (4.3%)
Symptom
(n = 2183)
Anilidesa (N02BE)559 (25.6%)
NSAID propionic acid derivatives (M01AE)121 (5.5%)
Proton pump inhibitors (A02BC)113 (5.2%)
Corticosteroids for nasal use (R01AD)105 (4.8%)
Other drugs for functional gastrointestinal disorders (A03AX)78 (3.6%)
Quality of life
(n = 534)
Anilidesa (N02BE)51 (9.6%)
Benzodiazepine derivatives (N05BA)32 (6.0%)
Benzodiazepine related drugs (N05CF)30 (5.6%)
Selective serotonin reuptake inhibitors (N06AB)30 (5.6%)
Proton pump inhibitors (A02BC)25 (4.7%)
Functioning
(n = 91)
Other anti-inflammatory and antirheumatic agents, non-steroids (M01AX)7 (7.7%)
Vitamin D and analogues (A11CC)4 (4.4%)
Anilidesa (N02BE)4 (4.4%)
Other nasal preparations (R01AX)4 (4.4%)
Other
(n = 60)
Progestogens and estrogens, fixed combinations (G03AA)9 (15.0%)
Progestogens and estrogens, sequential preparations (G03AB)6 (10.0%)
Bacterial and viral vaccines, combined (J07CA)3 (5.0%)
None
(n = 24)
Vitamin D and analogues (A11CC)4 (16.7%)
Antiseptics biguanides and amidines (D08AC)3 (12.5%)
Natural opium alkaloids (N02AA)2 (8.3%)
Anilidesa (N02BE)2 (8.3%)
Mucolytics (R05CB)2 (8.3%)
  1. aIncluding paracetamol